地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18995651644
传真：17754422825
邮箱：sales@amyjet.com
Rocky Mountain Diagnostics公司成立于2001年，主要产品涉及生物胺类、内分泌学、食品安全、研究分析/研究高敏感度、唾液试验、酶联免疫试剂盒等。
RMD was established in 2001 with a vision of marketing high quality in vitro diagnostics in the US. This vision, combined with the more than 40 years of experience of our partner organizations and exclusive dedication to immunodiagnostics, has made RMD together with its parent company the worldwide leaders in biogenic amine assays.
Rocky Mountain Diagnostics公司主要产品：
Biogenic Amines
Endocrinology
Food Safety - Featuring Histasure
Research Assays / Research High-Sensitive
Salivary Assays
Elisa Kit
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://pelfreez.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Rocky Mountain Diagnostics"> Rocky Mountain Diagnostics
艾美捷科技代理Badrilla 品牌。
Badrilla公司拥有一支由经验丰富的科学家和工程师组成的研发团队，他们在心血管研究领域具有深厚的专业知识和丰富的实践经验，特别是蛋白质S-棕榈酰化在疾病中的作用，并确保在您的实验系统中准确、精确和可靠地测量生物标志物浓度。Badrilla公司的主要产品包括用于心血管研究的各种高质量试剂和工具。这些产品旨在帮助研究人员深入了解心血管系统的生理和病理过程，从而推动心血管疾病的治疗和预防。
具体来说，Badrilla公司的产品和服务可能涵盖以下几个方面：
（1）蛋白质研究工具：提供高质量的蛋白质试剂，帮助研究人员研究蛋白质的结构和功能，以及蛋白质在心血管疾病中的作用。
（2）心血管研究试剂：包括用于研究心肌兴奋-收缩耦联、心律失常、心肌肥大和心脏衰竭等心血管疾病的试剂。
（3）定制服务：根据研究人员的具体需求，提供定制化的试剂和服务，以满足其独特的研究需求。
<<< " data-original="http://pelfreez.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Badrilla品牌"> 艾美捷科技代理Badrilla品牌
艾美捷科技代理代理MYOCEA品牌产品。
MYOCEA是一家专注于肌肉生物学和细胞培养技术的公司，致力于为科研和工业应用提供创新的肌肉细胞模型和相关产品。MYOCEA 以其独特的MyoCells™技术平台而闻名，该平台能够生成高度功能化的肌肉细胞，广泛应用于药物开发、毒理学测试、食品科学和再生医学等领域。MyoCells™技术平台能够生成与体内肌肉细胞高度相似的体外模型，为研究肌肉生物学和相关疾病提供了强大的工具。MYOCEA主要产品和技术包括：
（1）MyoCells™ 平台
MyoCells™ 肌肉细胞，高度功能化的肌肉细胞，具有与体内肌肉相似的生理特性。
MyoCells™ 培养基，专为肌肉细胞优化，支持细胞生长和功能维持。
MyoCells™ 试剂盒，包含细胞、培养基和实验指南，方便用户快速开展实验。
（2）药物开发工具
肌肉毒性测试，用于评估药物对肌肉细胞的毒性。
肌肉功能分析，提供高灵敏度的收缩性和代谢活性检测工具。
个性化药物筛选，基于患者来源的肌肉细胞模型，支持个性化医疗研究。
（3）食品科学应用
细胞培养肉研究，提供高质量的肌肉细胞，用于细胞培养肉开发。
食品添加剂测试，用于评估食品添加剂对肌肉细胞的影响。
（4）再生医学工具
肌肉再生研究，提供肌肉细胞模型，用于研究肌肉再生和修复机制。
组织工程，支持肌肉组织工程和生物材料开发。
（5）定制服务
定制肌肉细胞模型，根据客户需求开发特定的肌肉细胞模型。
合同研究服务（CRO），提供从实验设计到数据分析的全流程服务。
艾美捷科技代理rPeptide品牌全系列重组蛋白及多肽产品。
rPeptide公司提供高质量的肽、试剂、蛋白质、抗体等，专注于老年痴呆症和帕金森病的研究。rPeptide专有的平台载体技术能够在大肠杆菌中以可溶性肽/蛋白质的形式重组表达困难的肽/蛋白质。rPeptide还提供大量的β-淀粉样蛋白、taus、突触核蛋白、钙调素、定制产品等。
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
rPeptide产品详情请见艾美捷科技丁香通商城：
https://vicbio.biomart.cn/supply/c_282851.htm
<| Beta Amyloid 7E7 50ug and Beta Amyloid (1-40)NH4OH .25mg | BA-1101-1 | 50ug |
| Beta Amyloid 7E7 100ug and Beta Amyloid (1-40)NH4OH .5mg | BA-1101-2 | 100ug |
| Beta Amyloid 7E7 .5mg and Beta Amyloid (1-40)NH4OH .5mg | BA-1101-3 | 0.5mg |
| Beta Amyloid 7E7 1.0mg and Beta Amyloid (1-40)NH4OH 1.0mg | BA-1101-4 | 1.0mg |
| Beta Amyloid 7E7 50ug and Beta Amyloid (1-42)NH4OH .25mg | BA-1102-1 | 50ug |
| Beta Amyloid 7E7 100ug and Beta Amyloid (1-42)NH4OH .5mg | BA-1102-2 | 100ug |
| Beta Amyloid 7E7 .5mg and Beta Amyloid (1-42)NH4OH .5mg | BA-1102-3 | 0.5mg |
| Beta Amyloid 7E7 1.0mg and Beta Amyloid (1-42)NH4OH 1.0mg | BA-1102-4 | 1.0mg |
| Beta Amyloid 6C2 50ug and Beta Amyloid (1-40)NH4OH .25mg | BA-2201-1 | 50ug |
| Beta Amyloid 6C2 100ug and Beta Amyloid (1-40)NH4OH .5mg | BA-2201-2 | 100ug |
| Beta Amyloid 6C2 .5mg and Beta Amyloid (1-40)NH4OH .5mg | BA-2201-3 | 0.5mg |
| Beta Amyloid 6C2 1.0mg and Beta Amyloid (1-40)NH4OH 1.0mg | BA-2201-4 | 1.0mg |
| Beta Amyloid 6C2 50ug and Beta Amyloid (1-42)NH4OH .25mg | BA-2202-1 | 50ug |
| Beta-Amyloid 6C2, 100ug and Beta Amyloid (1-42) NH4OH 0.5mg | BA-2202-2 | 100ug |
| Beta Amyloid 6C2 .5mg and Beta Amyloid (1-42)NH4OH .5mg | BA-2202-3 | 0.5mg |
| Beta Amyloid 6C2 1.0mg and Beta Amyloid (1-42)NH4OH 1.0mg | BA-2202-4 | 1.0mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-02 | 1 x .25mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-1 | 1 x 0.5mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-2 | 1 x 1.0mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-02 | 1 x .25 mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-1 | 1 x 0.5 mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-2 | 1 x 1.0 mg |
| Beta-Amyloid (1-40), Mouse, Rat | A-1007-1 | 0.5 mg |
| Beta-Amyloid (1-40), Starter Kit | A-1150-1 | 5 x 0.5 mg |
| Beta-Amyloid (1-40), Starter Kit | A-1150-2 | 5 x 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, HCl | A-1156-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, HCl | A-1156-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, HFIP | A-1153-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, HFIP | A-1153-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, NaOH | A-1155-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, NaOH | A-1155-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, TFA | A-1001-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, TFA | A-1001-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-02 | 250 ug |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-2 | 1 mg |
| Beta-Amyloid (1-40, D23N) | A-1013-1 | 100 µg |
| Beta-Amyloid (1-40, D23N) | A-1013-2 | 1.0 mg |
| Beta-Amyloid (1-40, F4W) | A-1011-1 | 100 µg |
| Beta-Amyloid (1-11) | A-1051-1 | 1.0 mg |
| Beta-Amyloid (1-11) | A-1051-2 | 5.0 mg |
| Beta-Amyloid (1-16) | A-1052-1 | 1.0 mg |
| Beta-Amyloid (1-16) | A-1052-2 | 5.0 mg |
| Beta-Amyloid (1-28) | A-1053-1 | 0.5 mg |
| Beta-Amyloid (1-28) | A-1053-2 | 1.0 mg |
| Beta-Amyloid (1-38) | A-1078-1 | 0.5 mg |
| Beta-Amyloid (1-38) | A-1078-2 | 1.0 mg |
| Beta-Amyloid (11-22) | A-1055-1 | 1.0 mg |
| Beta-Amyloid (11-22) | A-1055-2 | 5.0 mg |
| Beta-Amyloid (11-40) | A-1061-2 | 1.0 mg |
| Beta-Amyloid (11-40), Mouse, Rat | A-1062-01 | 0.1 mg |
| Beta-Amyloid (11-40), Mouse, Rat | A-1062-1 | 0.5 mg |
| Beta-Amyloid (11-42) | A-1063-2 | 1.0 mg |
| Beta-Amyloid (12-28) | A-1056-1 | 0.5 mg |
| Beta-Amyloid (12-28) | A-1056-2 | 1.0 mg |
| Beta-Amyloid (17-40) | A-1057-1 | 0.5 mg |
| Beta-Amyloid (17-40) | A-1057-2 | 1.0 mg |
| Beta-Amyloid (17-42) | A-1058-1 | 0.5 mg |
| Beta-Amyloid (17-42) | A-1058-2 | 1.0 mg |
| Beta-Amyloid (22-35) | A-1059-1 | 1.0 mg |
| Beta-Amyloid (22-35) | A-1059-2 | 5.0 mg |
| Beta-Amyloid (25-35) | A-1060-1 | 1.0 mg |
| Beta-Amyloid (25-35) | A-1060-2 | 5.0 mg |
| 13C Beta-Amyloid (1-40), Uniformly labeled | A-1105-1 | 0.5 mg |
| 13C Beta-Amyloid (1-40), Uniformly labeled | A-1105-2 | 1.0 mg |
| 13C Beta-Amyloid (1-42), Uniformly labeled | A-1106-1 | 0.5 mg |
| 13C Beta-Amyloid (1-42), Uniformly labeled | A-1106-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-01 | 0.1 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-42), Uniformly labeled | A-1104-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-42), Uniformly labeled | A-1104-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-43), Uniformly labeled | A-1108-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-43), Uniformly labeled | A-1108-2 | 1.0 mg |
| 13C, Beta-Amyloid (1-43), Uniformly labeled | A-1109-1 | 0.5 mg |
| 13C, Beta-Amyloid (1-43), Uniformly labeled | A-1109-2 | 1.0 mg |
| 15N Beta-Amyloid (1-38), U. label | A-1147-1 | 0.1 mg |
| 15N Beta-Amyloid (1-38), U. label | A-1147-2 | 1.0 mg |
| 15N Beta-Amyloid (1-40), Rat, U. labeled | A-1131-1 | 0.5 mg |
| 15N Beta-Amyloid (1-40), Uniformly labeled | A-1101-1 | 0.1 mg |
| 15N Beta-Amyloid (1-40), Uniformly labeled | A-1101-2 | 1.0 mg |
| 15N Beta-Amyloid (1-42), Rat, U. labeled | A-1134-1 | 0.1 mg |
| 15N Beta-Amyloid (1-42), Rat, U. labeled | A-1134-2 | 1.0 mg |
| 15N Beta-Amyloid (1-42), Uniformly labeled | A-1102-1 | 0.1 mg |
| 15N Beta-Amyloid (1-42), Uniformly labeled | A-1102-2 | 1.0 mg |
| 15N Beta-Amyloid (1-43), Uniformly labeled | A-1107-1 | 1.0 mg |
| 15N Beta-Amyloid (1-46), U. label | A-1179-1 | 0.1 mg |
| 15N Beta-Amyloid (1-46), U. label | A-1179-2 | 0.5 mg |
| 15N Beta-Amyloid (11-40), Rat, U. label | A-1140-1 | 1.0 mg |
| 15N Beta-Amyloid (11-40), Uniformly labeled | A-1137-1 | 1.0 mg |
| 15N Beta-Amyloid (11-42), U. label | A-1120-2 | 1.0 mg |
| Biotin-Beta-Amyloid (1-40) | A-1111-01 | 0.1 mg |
| Biotin-Beta-Amyloid (1-40) | A-1111-2 | 1.0 mg |
| Biotin-Beta-Amyloid (1-42) | A-1117-1 | 0.5 mg |
| Biotin-LC-Beta-Amyloid (1-40) | A-1112-1 | 0.5 mg |
| Biotin-LC-Beta-Amyloid (1-40) | A-1112-2 | 1.0 mg |
| Biotin-LC-Beta-Amyloid (1-42) | A-1118-1 | 0.5 mg |
| Fluorescein-Beta-Amyloid (1-40) | A-1113-1 | 0.5 mg |
| Fluorescein-Beta-Amyloid (1-42) | A-1119-1 | 0.5 mg |
| Calmodulin, Porcine, Biotinylated | C-1002-1 | 100 µg |
| Calmodulin, Porcine, Fluorescein | C-1003-1 | 100 µg |
| Calmodulin, Porcine, Rhodamine | C-1004-1 | 100 µg |
| Calmodulin, Wheat (Triticum aestivum), Biotinylated | C-1008-1 | 50 µg |
| Calmodulin, Wheat (Triticum aestivum), Fluorescein | C-1009-1 | 50 µg |
| Calmodulin, Wheat (Triticum aestivum), Rhodamine | C-1010-1 | 50 µg |
| 15N Tau-441 (2N4R) Uniform Labeled | T-1101-1 | 50ug |
| 15N Tau-441 (2N4R) Uniform Labeled | T-1101-2 | 100ug |
| Tau Protein Ladder, of all 6 isoforms | T-1007-1 | 50 µl |
| Tau Protein Ladder, of all 6 isoforms | T-1007-2 | 100 µl |
| Tau Starter Kit | T-1170-1 | 50 µg |
| Tau Starter Kit | T-1170-2 | 100 µg |
| Tau-352, (0N3R) | T-1006-1 | 50 µg |
| Tau-352, (0N3R) | T-1006-2 | 100 µg |
| Tau-381, (1N3R) | T-1004-1 | 50 µg |
| Tau-381, (1N3R) | T-1004-2 | 100 µg |
| Tau-383, (0N4R) | T-1005-1 | 50 µg |
| Tau-383, (0N4R) | T-1005-2 | 100 µg |
| Tau-410, (2N3R) | T-1002-1 | 50 µg |
| Tau-410, (2N3R) | T-1002-2 | 100 µg |
| Tau-412, (1N4R) | T-1003-1 | 50 µg |
| Tau-412, (1N4R) | T-1003-2 | 100 µg |
| Tau-441, (2N4R) | T-1001-1 | 50 µg |
| Tau-441, (2N4R) | T-1001-2 | 100 µg |
| Tau-441, (2N4R), G272V mutant | T-1013-1 | 50 µg |
| Tau-441, (2N4R), P301L mutant | T-1014-1 | 50 µg |
| Tau-441, (2N4R), R406W mutant | T-1011-1 | 50 µg |
| Tau-441, (2N4R), V248L mutant | T-1015-1 | 50 µg |
| Tau-441, (2N4R), V337M mutant | T-1012-1 | 50 µg |
| Tubulin, Porcine | T-1201-1 | 1.0 mg |
| Latherin | L-1001-1 | 50ug |
| Latherin | L-1001-2 | 100ug |
| Latherin | L-1001-3 | 0.5mg |
| 15N, Alpha-Synuclein, Uniform Label | S-1004-1 | 0.5 mg |
| 15N, Alpha-Synuclein, Uniform Label | S-1004-2 | 1.0 mg |
| 15N, Beta-Synuclein, Uniform Label | S-1102-1 | .5mg |
| 15N, Beta-Synuclein, Uniform Label | S-1102-2 | 1.0mg |
| Alpha Synuclein Mouse | S-1010-1 | 0.5mg |
| Alpha Synuclein Mouse | S-1010-2 | 1.0mg |
| Alpha-Synuclein | S-1001-1 | 0.5 mg |
| Alpha-Synuclein | S-1001-2 | 1.0 mg |
| Alpha-Synuclein, 1-60 | S-1011-1 | 0.5 mg |
| Alpha-Synuclein, 1-95 | S-1012-1 | 0.5 mg |
| Alpha-Synuclein, 112 (NACP 112) | S-1016-1 | 0.5 mg |
| Alpha-Synuclein, 61-140 | S-1013-1 | 0.5 mg |
| Alpha-Synuclein, 96-140 | S-1014-1 | 0.5 mg |
| Alpha-Synuclein, A30P mutant | S-1005-1 | 0.5 mg |
| Alpha-Synuclein, A30P mutant | S-1005-2 | 1.0 mg |
| Alpha-Synuclein, A30P, A53T mutant | S-1006-1 | 0.5 mg |
| Alpha-Synuclein, A30P, A53T mutant | S-1006-2 | 1.0 mg |
| Alpha-Synuclein, A53T mutant | S-1002-1 | 0.5 mg |
| Alpha-Synuclein, A53T mutant | S-1002-2 | 1.0 mg |
| Alpha-Synuclein, Delta NAC | S-1015-1 | 0.5 mg |
| Alpha-Synuclein, E46K mutant | S-1008-1 | 0.5 mg |
| Alpha-Synuclein, E46K mutant | S-1008-2 | 1.0 mg |
| Beta-Synuclein | S-1003-1 | 0.5 mg |
| Beta-Synuclein | S-1003-2 | 1.0 mg |
| Gamma-Synuclein | S-1007-1 | 0.5 mg |
| Gamma-Synuclein | S-1007-2 | 1.0 mg |
| Gamma-Synuclein, Mouse | S-1009-1 | 0.5 mg |
| Gamma-Synuclein, Mouse | S-1009-2 | 1.0 mg |
| APP 669-711, HCl | AP-1156-1 | 0.5mg |
| APP 669-711, HCl | AP-1156-2 | 1.0mg |
| APP 669-711, HFIP | AP-1153-1 | 0.5mg |
| APP 669-711, HFIP | AP-1153-2 | 1.0mg |
| APP 669-711, N15 Uniformly Labelled | AP-1101-1 | 0.5mg |
| APP 669-711, N15 Uniformly Labelled | AP-1101-2 | 1.0mg |
| APP 669-711, NaOH | AP-1155-1 | 0.5mg |
| APP 669-711, NaOH | AP-1155-2 | 1.0mg |
| APP 669-711, NH4OH | AP-1157-1 | 0.5mg |
| APP 669-711, NH4OH | AP-1157-2 | 1.0mg |
| APP 669-711, TFA | AP-1001-1 | 0.5mg |
| APP 669-711, TFA | AP-1001-2 | 1.0mg |
| Apolipoprotein E, Human Plasma, VLDL | A-2001-1 | 50 µg |
| Alpha 1 Antichymotrypsin | A-2002-1 | 100 µg |
| Alpha 1 Antitrypsin | A-2003-1 | 1.0 mg |
| Alpha 2 Macroglobulin | A-2004-1 | 1.0 mg |
| Chymotrypsin | A-2005-1 | 100 µg |
| Haptoglobin | A-2006-1 | 1.0 mg |
| Myeloperoxidase | A-2007-1 | 100 µg |
| Plasmin | A-2008-1 | 1.0 mg |
| Plasminogen | A-2009-1 | 1.0 mg |
| Transferrin | A-2010-1 | 100 mg |
| Calmodulin, Porcine | C-1001-1 | 1 mg |
| Calmodulin, Wheat (Triticum aestivum) & Porcine | C-1006-1 | 200 µl |
| Calmodulin-SH, Wheat (Triticum aestivum) | C-1007-1 | 250 µg |
| Calmodulin-SH, Wheat (Triticum aestivum), Immobilized | C-1011-1 | 200 µl |
| Alpha Synuclein 10C3 Antibody | SA-3001-1 | 100ug |
| Alpha Synuclein 10C3 Antibody | SA-3001-2 | 1mg |
| Alpha Synuclein 10D2 Antibody | SA-3003-1 | 100ug |
| Alpha Synuclein 10D2 Antibody | SA-3003-2 | 1mg |
| Alpha Synuclein 5G4 Antibody | SA-3002-1 | 100ug |
| Alpha Synuclein 5G4 Antibody | SA-3002-2 | 1mg |
| Alpha Synuclein pAB 63 Antibody | SA-3004-1 | 100ul |
| Alpha Synuclein pAB 63 Antibody | SA-3004-2 | 1ml |
| Tau 3G3 | TA-3012-1 | 100ug |
| Tau 3G3 | TA-3012-2 | 1 mg |
| Tau 4C10 | TA-3011-1 | 100ug |
| Tau 4C10 | TA-3011-2 | 1mg |
| Tau 9D8 Antibody | TA-3010-1 | 100ug |
| Tau 9D8 Antibody | TA-3010-2 | 1mg |
| Tau total 12C2 | TA-3015-1 | 100ug |
| Tau total 12C2 | TA-3015-2 | 1mg |
| Tau total 18B5 | TA-3016-1 | 100ug |
| Tau total 18B5 | TA-3016-2 | 1 mg |
| Tau total 4B5 | TA-3013-1 | 100ug |
| Tau total 4B5 | TA-3013-2 | 1mg |
| Tau total 7E5 | TA-3017-1 | 100ug |
| Tau total 7E5 | TA-3017-2 | 1mg |
| Tau total 8F10 | TA-3014-1 | 100ug |
| Tau total 8F10 | TA-3014-2 | 1 mg |
| Tau total pAB 64 | TA-3020-1 | 100ul |
| Tau total pAB 64 | TA-3020-2 | 1 mg |
| Tau-10D3 Antibody | TA-3004-1 | 100ug |
| Tau-10D3 Antibody | TA-3004-2 | 1mg |
| Tau-10F8 Antibody | TA-3007-1 | 100ug |
| Tau-10F8 Antibody | TA-3007-2 | 1mg |
| Tau-1A6 Antibody | TA-2001-1 | 50ug |
| Tau-1A6 Antibody | TA-2001-2 | 100ug |
| Tau-1A6 Antibody | TA-2001-3 | 1.0mg |
| Tau-1A6 Antibody Kit | TA-1101-1 | 50ug |
| Tau-1A6 Antibody Kit | TA-1101-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2002 | TA-1102-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2002 | TA-1102-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2004 | TA-1104-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2004 | TA-1104-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2005 | TA-1105-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2005 | TA-1105-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2006 | TA-1106-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2006 | TA-1106-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2007 | TA-1107-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2007 | TA-1107-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2008 | TA-1108-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2008 | TA-1108-2 | 100ug |
| Tau-1E7 Antibody | TA-3001-1 | 100ug |
| Tau-1E7 Antibody | TA-3001-2 | 1mg |
| Tau-1F3 Antibody | TA-3005-1 | 100ug |
| Tau-1F3 Antibody | TA-3005-2 | 1mg |
| Tau-2B11 Antibody | TA-3008-1 | 100ug |
| Tau-2B11 Antibody | TA-3008-2 | 1mg |
| Tau-4G11 Antibody | TA-1001-1 | 50ug |
| Tau-4G11 Antibody | TA-1001-2 | 100ug |
| Tau-4G11 Antibody | TA-1001-3 | 1.0mg |
| Tau-4G11 Antibody Kit | TA-1111-1 | 50ug |
| Tau-4G11 Antibody Kit | TA-1111-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1003 | TA-1113-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1003 | TA-1113-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1004 | TA-1114-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1004 | TA-1114-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1005 | TA-1115-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1005 | TA-1115-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1006 | TA-1116-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1006 | TA-1116-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1007 | TA-1117-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1007 | TA-1117-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1008 | TA-1118-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1008 | TA-1118-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1009 | TA-1119-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1009 | TA-1119-2 | 100ug |
| Tau-5G7 Antibody | TA-3009-1 | 100ug |
| Tau-5G7 Antibody | TA-3009-2 | 1mg |
| Tau-8B11 Antibody | TA-3002-1 | 100ug |
| Tau-8B11 Antibody | TA-3002-2 | 1mg |
| Tau-8D2 Antibody | TA-3003-1 | 100ug |
| Tau-8D2 Antibody | TA-3003-2 | 1mg |
| Tau-9C8 Antibody | TA-3006-1 | 100ug |
| Tau-9C8 Antibody | TA-3006-2 | 1mg |
| Tau-E2+E3 9E11 | TA-3019-1 | 100ug |
| Tau-E2+E3 9E11 | TA-3019-2 | 1mg |
| Tau-E3 2B6 | TA-3018-1 | 100ug |
| Tau-E3 2B6 | TA-3018-2 | 1mg |
| AK-7 | N-3003-1 | 5 mg |
| AK-7 | N-3003-2 | 25 mg |
| ANA-12 | N-3031-1 | 5 mg |
| ANA-12 | N-3031-2 | 25 mg |
| Apomorphine HCI Hemihydrate | N-3027-1 | 100 mg |
| Apomorphine HCI Hemihydrate | N-3027-2 | 500 mg |
| Benztropine Mesylate | N-3012-1 | 1 gm |
| Bexarotene | N-3032-1 | 10 mg |
| Bexarotene | N-3032-2 | 50 mg |
| C-646 | N-3002-1 | 5 mg |
| C-646 | N-3002-2 | 25 mg |
| C16 | N-3030-1 | 5 mg |
| C16 | N-3030-2 | 25 mg |
| Candesartan | N-2049-1 | 20mg |
| Candesartan | N-2049-2 | 100mg |
| Celastrol | N-2187-1 | 10mg |
| Celastrol | N-2187-2 | 50mg |
| CNEE | N-1062-1 | 5mg |
| CNEE | N-1062-2 | 25mg |
| CTPB | N-3001-1 | 5 mg |
| CTPB | N-3001-2 | 25 mg |
| DAPT | N-3018-1 | 5 mg |
| DAPT | N-3018-2 | 25 mg |
| Deoxymannojirimycin HCl | N-2798-1 | 1mg |
| Deoxymannojirimycin HCl | N-2798-2 | 5mg |
| Diazoxide | N-3026-1 | 100 mg |
| Diazoxide | N-3026-2 | 500 mg |
| DMOG | MC-2371-1 | 10mg |
| DMOG | MC-2371-2 | 50mg |
| DU-14 | N-1187-1 | 5mg |
| DU-14 | N-1187-2 | 25mg |
| Edaravone | N-3034-1 | 1 gm |
| Edaravone | N-3034-2 | 5 gm |
| Entacapone | N-2025-1 | 10mg |
| Entacapone | N-2025-2 | 50mg |
| Epoxycholesterol | N-1330-1 | 1mg |
| Epoxycholesterol | N-1330-2 | 5mg |
| Ferrostatin-1 | N-1380-1 | 5mg |
| Ferrostatin-1 | N-1380-2 | 25mg |
| Fingolimod | N-3025-1 | 5 mg |
| Fingolimod | N-3025-2 | 25 mg |
| FK-506 | N-3024-1 | 20 mg |
| FK-506 | N-3024-2 | 100 mg |
| FPS-ZM1 | N-1635-1 | 5mg |
| FPS-ZM1 | N-1635-2 | 25mg |
| Gabapentin lactam | N-2535-1 | 50mg |
| Gabapentin lactam | N-2535-2 | 250mg |
| Imatinib Mesylate | N-3020-1 | 20 mg |
| Imatinib Mesylate | N-3020-2 | 100 mg |
| ISO-1 | N-3017-1 | 10 mg |
| ISO-1 | N-3017-2 | 50 mg |
| ISRIB | N-1539-1 | 5mg |
| ISRIB | N-1539-2 | 25mg |
| ISX9 | N-3010-1 | 5 mg |
| ISX9 | N-3010-2 | 25 mg |
| IU1 | N-1197-1 | 10mg |
| IU1 | N-1197-2 | 50mg |
| LM11A-31 2HCI | N-3005-1 | 5 mg |
| LM11A-31 2HCI | N-3005-2 | 25 mg |
| LM22A-4 | N-3006-1 | 10 mg |
| LM22A-4 | N-3006-2 | 50 mg |
| Minocyline HCI | N-3013-1 | 50 mg |
| Minocyline HCI | N-3013-2 | 250 mg |
| Mithramycin A | N-2085-1 | 1mg |
| Mithramycin A | N-2085-2 | 5mg |
| Mitoquinone | N-1363-1 | 5mg |
| Mitoquinone | N-1363-2 | 25mg |
| Montelukast Sodium | N-3028-1 | 50 mg |
| Montelukast Sodium | N-3028-2 | 250 mg |
| Mycophenolate mofetil | N-2086-1 | 50mg |
| Mycophenolate mofetil | N-2086-2 | 250mg |
| Neurodazine | N-3014-1 | 5 mg |
| Neurodazine | N-3014-2 | 25 mg |
| Neuropathiazol | N-3015-1 | 5 mg |
| Neuropathiazol | N-3015-2 | 25 mg |
| Noopept | N-2682-1 | 10mg |
| Noopept | N-2682-2 | 50mg |
| P7C3 | N-3004-1 | 5 mg |
| P7C3 | N-3004-2 | 25 mg |
| Phenylbutyrate Na | MC-1118-1 | 1gm |
| Phenylbutyrate Na | MC-1118-2 | 5gm |
| Pinacidil | N-2856-1 | 10mg |
| Pinacidil | N-2856-2 | 50mg |
| Prostratin | N-3011-1 | 1 mg |
| Prostratin | N-3011-2 | 5 mg |
| Rapamycin | N-3022-1 | 20 mg |
| Rapamycin | N-3022-2 | 100 mg |
| Resveratrol | N-3019-1 | 100 mg |
| Resveratrol | N-3019-2 | 500 mg |
| Roscovitine | N-1332-1 | 5mg |
| Roscovitine | N-1332-2 | 25mg |
| Salirasib | N-1461-1 | 5mg |
| Salirasib | N-1461-2 | 25mg |
| SB-225022 | N-3016-1 | 5 mg |
| SB-225022 | N-3016-2 | 25 mg |
| Tianeptine | N-3008-1 | 10 mg |
| Tianeptine | N-3008-2 | 50 mg |
| Tolcapone | N-3007-1 | 10 mg |
| Tolcapone | N-3007-2 | 50 mg |
| TRO 19622 | N-3029-1 | 5 mg |
| TRO 19622 | N-3029-2 | 25 mg |
| Vildagliptin | N-2887-1 | 20mg |
| Vildagliptin | N-2887-2 | 100mg |
| Vorinostat | N-3021-1 | 50 mg |
| Vorinostat | N-3021-2 | 250 mg |
| Zileuton | N-3023-1 | 10 mg |
| Zileuton | N-3023-2 | 50 mg |
| Zolmitriptan | N-3033-1 | 10 mg |
| Zolmitriptan | N-3033-2 | 50 mg |
艾美捷科技代理G-Biosciences品牌。
G-Biosciences是一家专注于蛋白质组学研究的美国公司，产品广泛应用于学术研究和工业制造领域，包括：蛋白质检测、样品制备、电泳、蛋白质印迹、质谱、测定开发、抗体生产和蛋白质
纯化等。目前，G-Biosciences的高品质产品已经被超过25,000篇文章引用，并且这个数据还是不断增加。
G-Biosciences旨在提供试剂、特殊化学品、缓冲液、分析、应用试剂盒等各类研究工具；G-Biosciences还可以提供符合生物技术行业cGMP要求产品、高质量的定制和OEM制造。目前厂家
已经通过美国ISO9001：2015认证。
G-Biosciences公司产品包括：
（1）蛋白质组学：完整的蛋白质组学产品组合，包括蛋白质提取、分离和蛋白质色谱，到蛋白质标记和缀合和随后的蛋白质检测（蛋白质印迹和质谱）
（2）生物测定：用于测定开发和蛋白质检测的广泛的抗体、重组蛋白和ELISA库。细胞健康检测、SAM甲基转移酶、蛋白酶、磷酸酶和报告基因检测。
（3）DNA和RNA：大量基因组DNA和质粒DNA提取产品可供选择。RNA分离和净化试剂。经济实惠的PCR试剂，包括Taq和dNTPS。酵母DNA分离和转化试剂盒。
< " data-original="http://pelfreez.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理G-Biosciences品牌"> 艾美捷科技代理G-Biosciences品牌
艾美捷科技代理ImmunoStep品牌。
ImmunoStep是一家专注于流式细胞术和免疫学研究的生物技术公司，主要提供高质量的试剂和工具，支持免疫表型分析、细胞功能研究和临床诊断。ImmunoStep公司的产品与服务包括：
（1）流式细胞术试剂：
抗体：提供多种荧光标记的单克隆抗体，适用于人、小鼠、大鼠等物种。
染色缓冲液：优化细胞染色过程。
细胞活力染料：用于区分活细胞和死细胞。
（2）试剂盒：
免疫表型分析试剂盒：用于快速、多参数分析免疫细胞亚群。
细胞因子检测试剂盒：用于检测细胞内或分泌的细胞因子。
（3）定制服务：
抗体标记：根据客户需求定制荧光标记抗体。
面板设计：帮助客户设计多色流式细胞术实验面板。
" data-original="http://pelfreez.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理ImmunoStep品牌"> 艾美捷科技代理ImmunoStep品牌
艾美捷科技代理LifeSensors品牌。
LifeSensors成立于1996年，位于美国宾夕法尼亚州费城，是一家为药物发现与研究提供方法和可行性技术方法的生物技术公司。公司致力于为泛素和泛素蛋白酶体通路研究领域提供高品质
的抗体、酶、蛋白质等试剂和试剂盒，产品，是泛素研究者的好选择。
其原核和真核蛋白表达系统SUMOpro和SUMOstar已被世界范围内的学术、政府研究机构和制药、生物技术公司广泛应用。通过提供创新的研究工具，LifeSensors已成为泛素和泛素样蛋
白途径的优质供应商。
LifeSensors公司目前主要的产品有400多种，其产品主要覆盖泛素和泛素蛋白酶体通路等科学应用领域，并且产品线在不断的扩大中。公司开创了两大独家技术平台：用于细胞信号和药物
发现的泛素蛋白酶体系统(UPS)，以及增强目的蛋白在大肠杆菌、酵母、昆虫和哺乳动物细胞中表达与纯化的SUMO融合表达系统。泛素蛋白酶体系统正在成为继激酶之后，药物发现的下
一个机遇，必将成为未来许多新型药物的创新来源。作为泛素蛋白领域的先驱公司，药物的发现、分析化合物以及去泛素酶和泛素化酶的高通量筛选正是LifeSensors创新技术的真正亮点。
此外，LifeSensors还为泛素的蛋白质组学提供众多定制技术服务，并且已经开发了各种各样的测定细胞中的生理底物或生物标志物的方法。
< " data-original="http://pelfreez.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理LifeSensors品牌"> 艾美捷科技代理LifeSensors品牌
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年，提供近200种亚磷酰胺和核苷酸合成用固相交联单体，以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.
Berry & Associates的主要产品包括：
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://pelfreez.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
艾美捷科技代理Epredia品牌。
Epredia是一家全球性公司，致力于实现精准癌症诊断，Epredia的产品组合代表了整个组织学工作流程，从标本采集到处理，从切片到染色，从成像到存档。Epredia由Shandon、Microm、Menzel Gläser和Richard-Allan Scientific等品牌组成，拥有广泛的解决方案，这些解决方案已经并将继续改变解剖病理学市场。
Epredia的解决方案包括：
（1）组织处理和包埋解决方案：随着新的工作环境和人员配备挑战的出现，了解组织处理试剂如何节省时间并提高处理组织的质量至关重要。
（2）标签和跟踪解决方案：PrintMate AS™盒式打印机和SlideMate幻灯片打印机系列，减少因标签错误而出错的机会，并通过自动化的方式标记和跟踪实验室样本和幻灯片来简化工作流程。
（3）组合解决方案：Epredia一直在寻找简化工作流程的方法，同时增强结果。
（4）存档解决方案：存档是实验室中确保整个组织学工作流程中样本安全的重要过程。
< " data-original="http://pelfreez.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Epredia品牌"> 艾美捷科技代理Epredia品牌地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：15172469628
传真：13212737804
邮箱：sales@amyjet.com
0.181
<
